Pharmacotherapy of Comorbid Mood, Anxiety, and Substance Use Disorders
- 1 January 2005
- journal article
- review article
- Published by Taylor & Francis in Substance Use & Misuse
- Vol. 40 (13-14) , 2021-2041
- https://doi.org/10.1080/10826080500294924
Abstract
Mood and anxiety disorders commonly co-occur with substance use disorders. Exploration of the neurobiology of substance use disorders and mood and anxiety disorders have found that the neural circuitry in mood, anxiety, and substance use disorders is clearly overlapping. These discoveries have encouraged the exploration of a number of pharmacotherapeutic agents in the treatment of co-occurring mood, anxiety, and substance use disorders. In this article, recent data on the pharmacotherapeutic treatment of mood and anxiety disorders in individuals with substance use disorders are reviewed. Some of the barriers to the use of pharmacotherapy in individuals with substance use disorders are discussed.Keywords
This publication has 72 references indexed in Scilit:
- Potential Use of Olanzapine in Treatment of Substance Dependence DisordersJournal of Clinical Psychopharmacology, 2003
- A Randomized Trial of Sertraline as a Cessation Aid for Smokers With a History of Major DepressionAmerican Journal of Psychiatry, 2002
- The Association Between Substance Abuse and Antidepressant-Induced Mania in Bipolar DisorderThe Journal of Clinical Psychiatry, 2002
- Substance Use Disorders in Patients With Posttraumatic Stress Disorder: A Review of the LiteratureAmerican Journal of Psychiatry, 2001
- Exposure therapy in the treatment of PTSD among cocaine-dependent individualsJournal of Substance Abuse Treatment, 2001
- Compulsive Drug‐Seeking Behavior and RelapseAnnals of the New York Academy of Sciences, 2001
- Assessing the Risks and Benefits of Benzodiazepines for Anxiety Disorders in Patients with a History of Substance Abuse or DependenceThe American Journal on Addictions, 2001
- Treatment of Depressed Methadone Maintenance Patients with Nefazodone:A Case SeriesThe American Journal on Addictions, 1998
- Adherence to Lithium Prophylaxis: II. Multivariate Analysis of Clinical, Social, and Psychosocial Predictors of NonadherencePharmacopsychiatry, 1988
- Compliance with Long-term Lithium Treatment in Major Affective DisordersPharmacopsychiatry, 1987